Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar?

Abstract

1. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000; 46: 523–6. 2. Rybak MJ, Bailey EM, Lamp KC et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteraemia. Antimicrob Agents Chemother 1992; 36: 1109–14. 3. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24: 41–57. 4. Sauermann R, Rothenburger M, Graninger W et al. Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81: 79–91. 5. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245–9.